Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With nab-Sirolimus At Society Of Gynecologic Oncology
$AADI
Biotechnology: Pharmaceutical Preparations
Health Care
- Subgroup experienced efficacy and safety consistent with overall study population
- Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT
- Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers